Combining New Treatments to Improve Care for Lung Cancer Patients
NCT03851445 · RecruitingThis trial is studying ways to screen for targeted treatments in patients with previously treated non-small cell lung cancer. It will help find out which treatments work best based on specific cancer traits. The goal is to improve outcomes by comparing new therapies to standard care. It also includes options for patients who do not fit into the specific treatment groups.
Locations and contact
This trial is running at 1,229 locations. The first 8 are listed here.
- Veterans Administration Medical Center - BirminghamBirmingham, AlabamaRecruiting
- Gulf Health Hospitals Inc/Infirmary Cancer Care - MalbisDaphne, AlabamaRecruiting
- Thomas HospitalFairhope, AlabamaRecruiting
- Mobile Infirmary Medical CenterMobile, AlabamaRecruiting
- University of South Alabama Mitchell Cancer InstituteMobile, AlabamaSuspended
- Gulf Health Hospitals Inc/Infirmary Cancer Care - SaralandSaraland, AlabamaRecruiting
- Anchorage Associates in Radiation MedicineAnchorage, AlaskaRecruiting
- Anchorage Radiation Therapy CenterAnchorage, AlaskaSuspended
Who can join
Adults aged 18 and older, both men and women, with a confirmed diagnosis of non-small cell lung cancer can join. Participants should have Stage IV or recurrent disease and meet specific treatment history requirements. The trial team will confirm eligibility based on these criteria.
What happens during the trial
Participants will go through a screening process to see if they can join one of the treatment sub-studies. This study itself does not involve any treatment but helps assign patients to the right sub-study based on their cancer's characteristics. Each sub-study will then provide its own treatment options.
The trial team
The trial is led by the SWOG Cancer Research Network, with collaboration from the National Cancer Institute. Hossein Borghaei is the study chair overseeing the trial.
Important dates
The trial started on February 6, 2019, and is expected to finish by January 28, 2029. It is currently enrolling new participants.
Additional information
The trial's ID number is NCT03851445. It is a Phase 2 and 3 trial, which means it is looking at how well the treatments work and how safe they are. The trial is regulated by the FDA and aims to include around 10,000 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →